New and old markers of progression of diabetic nephropathy

Diabetes Research and Clinical Practice

Volumn 82, Issue SUPPL. 1, 2008, Pages

  Jerums, G ^a   Premaratne, E ^a   Panagiotopoulos, S ^a   Clarke, S ^a   Power, D A ^a   MacIsaac, R J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Albuminuria; Biological markers; Diabetic nephropathy; Glomerular filtration rate

Indexed keywords

ALBUMIN; CONNECTIVE TISSUE GROWTH FACTOR; CYSTATIN C; IRBESARTAN; LOSARTAN; PLACEBO; TRANSFORMING GROWTH FACTOR BETA;

ALBUMINURIA; ARTICLE; DIABETIC NEPHROPATHY; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; NONHUMAN; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ALBUMINURIA; BIOLOGICAL MARKERS; CYTOKINES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 55249089404     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.09.032     Document Type: Article

References (51)

1. Mogensen C.E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br. Med. J. (Clin. Res. Ed.) 285 (1982) 685-688
2. Hillege H.L., Fidler V., Diercks G.F., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106 (2002) 1777-1782
3. Atkins R.C., Polkinghorne K.R., Briganti E.M., et al. Prevalence of albuminuria in Australia: the AusDiab Kidney Study. Kidney Int. Suppl. (2004) S22-S24
4. Sviridov D., Meilinger B., Drake S.K., et al. Coelution of other proteins with albumin during size-exclusion HPLC: implications for analysis of urinary albumin. Clin. Chem. 52 (2006) 389-397
5. Mogensen C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. 310 (1984) 356-360
6. Parving H.H., Oxenboll B., Svendsen P.A., et al. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol. (Copenh.) 100 (1982) 550-555
7. Viberti G.C., Jarrett R.J., Mahmud U., et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1 (1982) 1430-1432
8. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39 (2002) S1-266
9. MacIsaac R.J., Tsalamandris C., Panagiotopoulos S., et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 27 (2004) 195-200
10. MacIsaac R.J., and Jerums G. Albuminuric and non-albuminuric pathways to renal impairment in diabetes. Miner. Endocrinol. 30 (2005) 161-177
11. Lane P.H., Steffes M.W., and Mauer S.M. Glomerular structure in IDDM women with low glomerular filtration rate and normal urinary albumin excretion. Diabetes 41 (1992) 581-586
12. Tsalamandris C., Allen T.J., Gilbert R.E., et al. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes 43 (1994) 649-655
13. Kramer H.J., Nguyen Q.D., Curhan G., and Hsu C.Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 289 (2003) 3273-3277
14. MacIsaac R., Panagiotopoulos S., McNeil K., et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?. Diabetes Care 29 (2006) 1560-1566
15. E. Premaratne, Methods and measurements of renal function in diabetes, MD Thesis, University of Melbourne, 2008.
16. Perkins B.A., Ficociello L.H., Ostrander B.E., et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J. Am. Soc. Nephrol. 18 (2007) 1353-1361
17. Rudberg S., Persson B., and Dahlquist G. Increased glomerular filtration rate as a predictor of diabetic nephropathy-an 8-year prospective study. Kidney Int. 41 (1992) 822-828
18. Berg U., and Thalme B. Long-term renal function in children with type 1 diabetes and its relation to development of micro- and macroalbuminuria. 20th Annual Meeting of the European Diabetic Nephropathy Study Group. Edinburgh (2007) 27
19. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
20. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med. 139 (2003) 137-147
21. Dharnidharka V.R., Kwon C., and Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am. J. Kidney Dis. 40 (2002) 221-226
22. Sarnak M.J., Katz R., Stehman-Breen C.O., et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann. Intern. Med. 142 (2005) 497-505
23. Shlipak M.G., Sarnak M.J., Katz R., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N. Engl. J. Med. 352 (2005) 2049-2060
24. MacDonald J., Marcora S., Jibani M., et al. GFR estimation using cystatin C is not independent of body composition. Am. J. Kidney Dis. 48 (2006) 712-719
25. Baxmann A.C., Ahmed M.S., Marques N.C., et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin. J. Am. Soc. Nephrol. 3 (2008) 348-354
26. MacIsaac R.J., Tsalamandris C., Thomas M.C., et al. The accuracy of cystatin C and commonly used creatinine-based methods for detecting moderate and mild chronic kidney disease in diabetes. Diabetic Med. 24 (2007) 443-448
27. Adler A.I., Stevens R.J., Manley S.E., et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 63 (2003) 225-232
28. Clarke S., Premaratne E., Panagiotopoulos S., et al. Low estimated glomerular filtration rate (eGFR) predicts 5-year mortality in type 2 diabetes. Proceedings of the Annual Scientific Meeting of the Australian Diabetes Society. Gold Coast, Australia (2006) A125
29. Eriksen B.O., and Ingebretsen O.C. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int. 69 (2006) 375-382
30. Mogensen C.E. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand. J. Clin. Lab. Invest. 36 (1976) 383-388
31. Parving H.H., Andersen A.R., Smidt U.M., and Svendsen P.A. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1 (1983) 1175-1179
32. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345 (2001) 861-869
33. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345 (2001) 851-860
34. Clarke S., Thomas M., MacIsaac R., et al. Rate of decline in glomerular filtration rate is independent of stage of nephropathy in type 2 diabetes, Proceedings of the 42nd Annual Scientific Meeting of the Australia and New Zealand Society of Nephrology, Melbourne, Australia. Nephrology 11 Suppl. (2006) A2551
35. MacIsaac R.J., Tsalamandris C., Thomas M.C., et al. Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia 49 (2006) 1686-1689
36. Premaratne E., MacIsaac R., Finch S., et al. Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes. Diabetes Care 31 (2008) 971-973 10.2337//dc07-1588
37. Gaede P., Vedel P., Parving H.H., and Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353 (1999) 617-622
38. Gaede P., Tarnow L., Vedel P., et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol. Dial. Transplant. 19 (2004) 2784-2788
39. Araki S., Haneda M., Koya D., et al. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes 56 (2007) 1727-1730
40. Rossing P., Hommel E., Smidt U.M., and Parving H.H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37 (1994) 511-516
41. Apperloo A.J., de Zeeuw D., and de Jong P.E. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int. Suppl. 45 (1994) S174-178
42. Jerums G., Panagiotopoulos S., Premaratne E., et al. Lowering of proteinuria in response to antihypertensive therapy predicts improved renal function in late but not in early diabetic nephropathy: a pooled analysis. Am. J. Nephrol. 28 (2008) 614-627
43. Stevens L., Greene T., and Levey A. Surrogate end points for clinical trials of kidney disease progression. Clin. J. Am. Soc. Nephrol. 1 (2006) 874-884
44. Ito Y., Aten J., Bende R.J., et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 53 (1998) 853-861
45. Gilbert R.E., Akdeniz A., Weitz S., et al. Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care 26 (2003) 2632-2636
46. Nguyen T.Q., Tarnow L., Andersen S., et al. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 29 (2006) 83-88
47. Langham R.G., Kelly D.J., Gow R.M., et al. Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition. Diabetes Care 29 (2006) 2670-2675
48. Roestenberg P., van Nieuwenhoven F.A., Wieten L., et al. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 27 (2004) 1164-1170
49. Susztak K., and Bottinger E.P. Diabetic nephropathy: a frontier for personalized medicine. J. Am. Soc. Nephrol. 17 (2006) 361-367
50. Dihazi H., Muller G.A., Lindner S., et al. Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin. Chem. 53 (2007) 1636-1645
51. Perkins B.A., Nelson R.G., Ostrander B.E., et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J. Am. Soc. Nephrol. 16 (2005) 1404-1412